© Copyright Acquisition International 2025 - All Rights Reserved.

Article Image - Evotec Announces Its Intent to Acquire Cyprotex Plc
Posted 26th October 2016

Evotec Announces Its Intent to Acquire Cyprotex Plc

Acquisition would add world-leading high-quality ADME-Tox services and strengthen Evotec's leadership in drug discovery

Mouse Scroll AnimationScroll to keep reading

Let us help promote your business to a wider following.

Evotec Announces Its Intent to Acquire Cyprotex Plc
Image

Evotec Announces Its Intent to Acquire Cyprotex Plc

Acquisition would add world-leading high-quality ADME-Tox services and strengthen Evotec’s leadership in drug discovery

– Evotec will pay approximately £ 55.36 m (EUR 62.00 m) in cash for the full share capital of Cyprotex and funding of all existing debt of the AIM-listed company

– Proposed acquisition, unanimously recommended by the board of Cyprotex, is expected to close before year-end 2016

Evotec AG (Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced that it has made an offer to acquire Cyprotex PLC (“Cyprotex”, AIM: CRX-GB), a specialist pre-clinical contract research organisation in ADME-Tox and DMPK. Cyprotex serves the industry’s increasing requirement for earlier drug screening, regulatory requirements and reducing the reliance on animal testing.

The proposed acquisition, which has been unanimously recommended by the board of Cyprotex, is expected to close before year-end 2016. Evotec will pay approximately £ 55.36 m (EUR 62.00 m; £/EUR exchange rate of 1.12) in cash for the acquisition of all 26.1 million issued and to be issued Cyprotex shares and the funding of all existing company debt. The offer of 1.60 £ per Cyprotex share reflects a 9.4% premium to the VWAP of the past 30 trading days at AIM. The offer is intended to be implemented by a scheme of arrangement regulated by the UK takeover code, with already >50% shares secured irrevocable. The acquisition will add to Evotec’s revenues and be accretive to Evotec’s 2017 EBITDA.

Cyprotex is the world’s largest contract research organisation specialising in pre-clinical ADME-Tox and DMPK serving the Pharmaceutical, Chemical, Agrochemical and Cosmetics markets. Cyprotex, headquartered in the UK, was founded in 1999 and is publicly traded on AIM (CRX). It has 136 employees working from sites at Macclesfield and Alderley Park, both of which are located near Manchester in the UK, and at Watertown, MA, and Kalamazoo, MI, in the USA. With more than 1,500 partners, Cyprotex has a very strong customer network. Cyprotex reported H1 2016 revenues of £ 8.73 m (EUR 9.78 m) (H1 2015: £ 6.93 m (EUR 7.76 m)) with an underlying EBITDA of £ 2.34 m (EUR 2.62 m) (H1 2015: £ 1.10 m (EUR 1.23 m)).

Sharpening Evotec’s leadership role in drug discovery The acquisition strengthens Evotec’s high-end drug discovery platform and capabilities with access to the market’s most industrialised ADME-Tox platform and proven expertise in in vitro ADME screening, mechanistic and high-content toxicology screening and predictive modelling.

This perfectly augments Evotec’s drive for innovation efficiency in drug discovery by enabling its partners to make early informed decisions on a molecule’s suitability for further development. The Cyprotex platform can be leveraged in a high-throughput manner or to support integrated drug discovery projects.

Dr Mario Polywka, Chief Operating Officer of Evotec, commented: “The ability to test or predict a molecule’s suitability as a drug at an early stage is critical in the drive to increase the efficiency of drug discovery.

The proposed acquisition of Cyprotex is a completely logical step to strengthen Evotec’s position as the world’s leading partner of choice for driving such efficiencies in drug discovery to the industry. The proven technology platform of Cyprotex and its expert and dedicated employees will be a strong addition to our best-in-class drug discovery platform and resources. We also expect that both organisations will leverage their extensive partner networks to identify further commercial synergies.”

Dr Werner Lanthaler, Chief Executive Officer of Evotec, added: “Our focus to make the most innovative and capital efficient drug discovery platform will be perfectly extended by Cyprotex. Given our strong performance over the last years, a very good outlook of our business into the coming years, and the commercial profile of Cyprotex we also feel very comfortable in using the cash on our strong balance sheet for this accretive acquisition. We are very much looking forward to welcoming the employees of Cyprotex within the Evotec Group after closing of the transaction.”

Categories: Innovation, Leadership


You Might Also Like
Read Full PostRead - Eye Icon
Bristow acquisition of Airnorth
Finance
19/03/2015Bristow acquisition of Airnorth

Bristow Group Inc. (NYSE: BRS), a leading provider of helicopter services to the worldwide offshore energy industry, announced that its affiliate, Bristow Helicopters Australia Pty Ltd., acquired an 85 - percent interest in Airnorth, [Inc., Ltd. and subsidiari

Read Full PostRead - Eye Icon
Enhancing Security and Efficiency: Integrating BIN Checker Tools into Payment Processing Systems
News
16/02/2024Enhancing Security and Efficiency: Integrating BIN Checker Tools into Payment Processing Systems

In the realm of online transactions, security and efficiency stand as the twin pillars upon which trust and reliability are built. As digital commerce continues to evolve, businesses and consumers alike demand robust safeguards against fraudulent activities wh

Read Full PostRead - Eye Icon
Steps You Can Take to Prevent and Mitigate Cybercrime in Your Company
Innovation
21/10/2022Steps You Can Take to Prevent and Mitigate Cybercrime in Your Company

In 2022, the war on cybercrime is continuing as criminals get savvier and continue to seek new ways to exploit businesses and the public online. Back in 2016, we noted here at Acquisition International that cybercrime was a looming threat. It's therefore no su

Read Full PostRead - Eye Icon
Iwoca Series-B led by by Acton Capital Partners
Finance
04/08/2015Iwoca Series-B led by by Acton Capital Partners

Iwoca Series-B led by by Acton Capital Partners

Read Full PostRead - Eye Icon
Antin Infrastructure to Buy BP’s stake in Central Area Transmission System
Finance
14/05/2015Antin Infrastructure to Buy BP’s stake in Central Area Transmission System

Antin Infrastructure to Buy BP’s stake in Central Area Transmission System

Read Full PostRead - Eye Icon
Pavilion Financial Corporation to Acquire Altius Holdings Ltd
Finance
28/06/2016Pavilion Financial Corporation to Acquire Altius Holdings Ltd

Pavilion Financial Corporation (Pavilion), a North American based employee-owned, investment services firm, today announced that it plans to acquire Altius Holdings Ltd., the parent company of Altius Associates Ltd. and Altius Associates (Singapore) Pte. Ltd.

Read Full PostRead - Eye Icon
Leading the New Frontier of Private Investment Management
Finance
05/08/2022Leading the New Frontier of Private Investment Management

Industry FinTech, the ‘Best Fund Administration’ for 2022 in Florida, has made a name for itself across the United States of America with its front-running, highly technologically enabled, and legally compliant services.

Read Full PostRead - Eye Icon
5 Strategies for Real Estate Agents to Thrive During the Holidays
News
19/11/20215 Strategies for Real Estate Agents to Thrive During the Holidays

The winter holidays make you think of home and the comfort of having your own place. As a real estate agent, you could say that this is the perfect time for connection and a bit of well-targeted marketing. While you may not have that many clients, specialists

Read Full PostRead - Eye Icon
How Are Assets and Investments Divided After a Divorce?
Legal
25/05/2023How Are Assets and Investments Divided After a Divorce?

Going through a divorce can be one of the most challenging experiences in life, and sorting out financial matters can make it even more complicated.



Our Trusted Brands

Acquisition International is a flagship brand of AI Global Media. AI Global Media is a B2B enterprise and are committed to creating engaging content allowing businesses to market their services to a larger global audience. We have a number of unique brands, each of which serves a specific industry or region. Each brand covers the latest news in its sector and publishes a digital magazine and newsletter which is read by a global audience.

Arrow